Follows adults with multiple myeloma in West-Occitanie through their care
Follows patients with multiple myeloma, recording their treatment, quality of life and daily care.
Plain-language title generated from the registry record
Registry title: Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
Key facts
- Where
- Toulouse, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults living in the West-Occitanie region who have been diagnosed with symptomatic multiple myeloma. It follows their care and quality of life.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Symptomatic multiple myeloma
Main reasons for not taking part
- Living outside the West-Occitanie region
- Opposed to taking part in the research
- Under legal protection
Read by machine on 12 November 2026.
Where in France
- IUCT-Oncopole - Toulouse University HospitalToulouse, FranceContact: Sandra BERNARD, PMTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT04888039
- Record updated
- 29 April 2026
- Original description
Actually very few real life data are available for patients with multiple myeloma (MM), whereas they're playing a more and more important role in health care decisions. Treatments choice for medical care of patient with MM depends of their age, their general status, their eligibility to high dose treatment (autograft), and also based on cytogenetic risk (standard/high risk). Therapeutic strategies are multiple and based on drugs associations including proteasome inhibitors, immuno-modulators and monoclonal antibodies.Read full original descriptionShow less
Therapeutic and Support Oncologic Medical Care Evaluation in Patients With Multiple Myeloma in West-Occitanie Region. Factors Influencing Medical Care and Predictive and Prognostic Impact.
Actually very few real life data are available for patients with multiple myeloma (MM), whereas they're playing a more and more important role in health care decisions. Treatments choice for medical care of patient with MM depends of their age, their general status, their eligibility to high dose treatment (autograft), and also based on cytogenetic risk (standard/high risk). Therapeutic strategies are multiple and based on drugs associations including proteasome inhibitors, immuno-modulators and monoclonal antibodies.
Therapeutic medical care objective is to improve quality and response duration through more effective induction schemas, systematic consolidation for patients who have undergone high dose therapy and/or maintenance treatment, ensuring patients safety and well-being in the health care pathway.
Quality of life evaluation has to take in consideration disease outcome and secondary effects impact from treatments prescribed for MM.
With clinical trials, new therapeutic strategies are proposed with innovative drugs but participants are selected and do not represent all patients with MM. Therefore, there is a large gap between clinical trials and real life data.
That's why the CHU Toulouse intends to set up a prospective cohort to evaluate the health care pathway of patients with MM in West-Occitanie region and studies impact of treatments prescribed on the disease and on the patients' quality of life.
With this research, standard of care practices for patients with MM will be followed, prognostic scores and clinical trials results will be validated in real life, impact of outpatient support procedure will be assessed (AMA procedure) and sociodemographic/quality of life data will be available for research teams.
Inclusion: Patient living in the West-Occitanie region; Patient with a diagnosis of symptomatic multiple myeloma (Rajkumar et al, Lancet Oncology 2014).
Exclusion: Patient opposed to this research; Patient under legal protection.